Neonatal Drug Therapy Manual

Amphotericin B Liposome

Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Original Date: 
April 2012
Revised Date: 
  • Treatment of severe fungal infections and/or deep mycoses in patients:
    • who fail to respond to conventional amphotericin B
    • who develop nephrotoxicity after conventional amphotericin B
    • in whom conventional amphotericin B is contraindicated because of renal impairment
  • IV intermittent infusion: over 2 hours
  • 3 - 5 mg/kg/day once daily
Side Effects: 
  • CNS: fever
  • CVS: hypotension, arrhythmias, vasodilatation, hypertension, tachycardia, edema, bradycardia
  • Endocrine and metabolic: hypokalemia, hypomagnesemia, hyperglycemia, hypocalcemia, hyperphosphatemia, hyponatremia
  • Hematologic: anemia, thrombocytopenia, leukopenia
  • Hepatic: ALT increased, AST increased, alkaline phosphatase increased, bilirubinemia
  • Local: phlebitis, injection site inflammation
  • Renal: renal tubular acidosis, serum creatinine increased, BUN increased, oliguria, hematuria
  • Miscellaneous: anaphylactoid and other allergic reactions
Parameters to Monitor: 
  • serum creatinine, BUN, urine output
  • serum electrolytes (particularly magnesium and potassium)
  • liver function tests
  • CBC
Reconstitution and Stability: 
  • Amphotericin B Liposome 50 mg
    • Add 12 mL SWFI.  Shake vigorously for 30 seconds.
    • Take 10 mL (40 mg) and using a 5 microns filter on the syringe add to 10 mL of D5W
    • Final concentration: 2 mg/mL

- Solutions Compatible: Dextrose solutions up to D25W

- Incompatible:  Saline solutions.  Do not mix with other drugs


- Taketomo CK, Hodding JH, Kraus DM.  Pediatric Dosage Handbook 17th Edition.  Hudson: Lexi-Comp Inc; 2010

- Lau E. (Editor). Drug Handbook and Formulary- The Hospital for Sick Children.  Toronto: 2011- 2012

- Juster-Reicher A, Flidel-Rimon O, Amitay M, Even-Tov S, Shinwell E, Leibovitz E.  High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates.  Eur J Clin Microb Dis 2003 Oct; 22(10): 603-7

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.